One hundred anestrous mares (early February) were injected S.C. with implants containing 0, .9, 1.8, 3.6, or 5.4 mg of a GnRH analogue (goserelin acetate) in an attempt to induce ovarian cyclicity. Follicular activity and concentrations of progesterone and LH were determined every 3 d, or daily during estrus. In treated mares that ovulated, the interval to the second ovulation of the season was compared to that for an additional group receiving 16 h/d of light beginning December 16 (positive controls). Of the mares that did not ovulate in 30 d, eight from each dose group were challenged on d 33 or 34 with an i.v. bolus of 950 pg of GnRH. Blood collected a t -2, -1, and 0 h before GnRH and at 15, 30, 45, 60, and 90 min and 2, 3, and 4 h after injection was assayed for serum LH. More mares ( P < .05) ovulated when given 3.6-( n = 7 ) or 5.4-mg ( n = 6 ) implants than when given .9-mg implants ( n = 0 1 or placebo ( n = 0). Mares with initial follicles 5 15 mm in diameter were less ( P < .05) likely to ovulate (10 of 8 8 ) than were those with follicles 16 to 20 mm in diameter ( 5 of 12). Area under the curve (AUC) for LH was greater for mares receiving larger doses of GnRH. The AUC and peak LH were similar between ovulating and nonovulating mares. Luteinizing hormone peaked in all mares on approximately d 12. There was no difference ( P > .05) in either peak LH or AUC among treatment groups in response to the GnRH challenge. Ovulating mares had extended interovulatory intervals (mean of 71.4 d ) compared with positive control mares (mean of 21.5 d). In summary, ovulation in response to GnRH depended on both GnRH dose administered and prior ovarian status.
Introduction
Winter anestrus and prolonged transition to normal ovarian cyclicity in the spring are common problems in the equine industry. Providing mares with 16 h/d of light beginning in December shortens the anestrous period (Palmer et al., 1982) . An exogenous hormone treatment that would hasten the onset of normal cyclicity would be beneficial.
Treatment of anestrous mares with GnRH and GnRH analogues, either by continuous infusion (Hyland et al., 19881 , pulsatile infusion (Johnson, 1987; Becker and Johnson, 19921 , slow-release implants (Harrison et al., 1990; Meyer et al., 19901 , or frequent injection (Bergfelt and Ginther, 1992) , have been reported. Meyer et al. (1990) reported an ' Financial support provided by CoopersPitman-Moore, Kansas ' To whom correspondence should be addressed: Equine Science 3~o o p e r s~i t r n a n -~~o o r e , Kansas City, KS.
J. h i m . Sci. 1994. 72:178-183 increased frequency of ovulation and decreased interval to ovulation when anestrous mares were given a slow-release implant of the GnRH analogue goserelin acetate. The objectives of this study were 1) t o further evaluate the response of mares to implants containing various doses of goserelin acetate and 2 ) to determine the effect of treatment dose on pituitary LH release in response to a GnRH challenge. The hypotheses tested were that higher doses of goserelin acetate would 1) result in a higher frequency of ovulation and 2 ) increase releasable pituitary LH.
Materials and Methods
One hundred twenty nonlactating, reproductively sound, anestrous light-horse mares were used. Mares were maintained on winter pasture and fed 2 kg of grain mix per mare per day. Mares had constant access to mixed grass-alfalfa hay, water, and salt/ mineral blocks.
Mares were evaluated with a stallion, and ovaries were palpated and scanned ultrasonographically per rectum twice weekly beginning on December 20, 1991, to determine stage of cycle. Blood was collected from each mare twice weekly, and serum was assayed for concentrations of progesterone (Martin et al., 1989) and LH (Hoffman et al., 1989) . Any mare developing an ovarian follicle of > 20 mm in diameter or having serum progesterone 2 1 ng/mL at any time during the 6-wk pretreatment period was excluded from the study.
Twenty mares were excluded based on the above criteria, and the remaining 100 mares were randomly divided into two replicates ( n = 50 per replicate). Mares in each replicate were housed separately but otherwise managed equivalently. Within each replicate, mares were sorted 5 d before the day of treatment according to the size of their largest ovarian follicle (< 10 mm or 10 to 20 mm in diameter) then randomly assigned within each follicle size category t o one of five treatment groups ( 0 , .9, 1.8, 3.6, or 5.4 mg per implant of goserelin acetate, D-ser(But)6AzoGly NHzlO-LHRH (CH690030;Coopers/Pitman-Moore, Kansas City, KS). Implants were designed to release analogue at a constant rate for 28 d. Implants were inserted subcutaneously in the neck using prepackaged needle-syringe units containing either goserelin depot or no hormone on February 5 (Replicate 1) or February 7 (Replicate 21, 1992. Identities of the treatments were not revealed until after completion of the study.
After treatment, blood was collected, mares were evaluated with a stallion, and ovaries were palpated and scanned ultrasonographically per rectum either every 3 d, daily during estrus, or daily if a follicle 2 35 mm in diameter developed.
The injection site was examined subjectively on each palpation day for signs of a tissue reaction. All blood samples were collected via jugular venipuncture into Vacutainer@ tubes (#6432, Becton Dickinson, Rutherford, NJ), held at room temperature for 2 2 h, and then refrigerated overnight. Samples were then centrifuged, and the serum was removed and frozen before it was assayed for concentrations of LH (Hoffman et al., 1989) and progesterone (Martin et al., 1989) . Mares were weighed and body conditions scored twice during the 6-wk pretreatment period, again at the time of treatment, and again at the end of the study.
OvuZating Mares
Any mare that ovulated during the 30-d posttreatment period was palpated and evaluated ultrasonographically per rectum on d 5, 8, and 11 after ovulation. Blood was collected on those days, and the serum was assayed for progesterone (Niswender, 1973) . Eight mares that had received 16 h/d of natural and artificial light from December 16, 1991, but no GnRH, served as positive controls for the GnRH-treated mares that ovulated. Blood was collected from positive-control mares on d 5 , 8, and 11 after their first ovulation of the year and serum concentrations of progesterone were determined (Niswender, 1973) . Interval to the second ovulation of the year (interovulatory interval) was recorded for all ovulating mares.
Nonovulating Mares
Of the 85 mares that did not ovulate during the 30-d posttreatment period, eight were randomly selected from each dose group regardless of replicate and challenged on d 33 or 34 after treatment with 950 pg of GnRH (LHRH acetate salt #L7134; Sigma Chemical, St. Louis, MO). On each challenge day, indwelling jugular catheters were inserted and sutured in place 2 h before the first blood collection. Catheters were kept patent with 2 mL of 5% heparinized saline injected after each collection. Blood was collected at -2 and -1 h, immediately before GnRH injection ( 0 h ) , and at 15, 30, 45, 60, and 90 min and 2, 3, and 4 h after GnRH injection. Each 10-mL sample was collected from the catheter after 2 mL had been drawn and discarded to eliminate heparin contamination. Blood samples were handled as before, but serum was assayed for LH immediately without freezing (Nett et al., 1975) . Net area under the postchallenge LH curve ( AUC) was determined for each mare by subtracting baseline LH (mean of the pretreatment samples) from total AUC obtained using the trapezoidal method. Peak LH attained during the postchallenge period was determined for each mare.
Statistical Analyses
Chi-square analysis was used to evaluate the effect of replicate and dose on frequency of ovulation and on development of a follicle 2 30 mm in diameter at any time during the posttreatment period, as well as t o evaluate the effect of mean follicle size before treatment (mean diameter of the largest follicle present per mare on each of the three palpations before treatment) on frequency of ovulation. All chi-square analyses were corrected for continuity due to the small counts occurring in some of the comparisons.
One-way ANOVA were used t o compare interval to ovulation, size of the largest follicle attained during the period after treatment, and net area under the LH curve (computed for each mare by subtracting the mean of the five pretreatment samples from total AUC) among treatment dose groups. In three mares (one each from the .9-, 3.6-, and 5.4-mg groups), net AUC was a negative number because of unusually high pretreatment serum concentrations of LH; these data were removed from analyses. One-way ANOVA were used to compare interovulatory interval between treated mares that ovulated and positive control mares and AUC for LH and mean peak LH among groups in response to GnRH challenge. --a*bValues within a column lacking a common superscript differ ( P < .05).
Repeated measures ANOVA were used to compare follicle numbers and serum concentrations of LH among groups over time in mares that did not ovulate and postovulation serum concentrations of progesterone among groups over time. Scheffe's test was used to compare all means when ANOVA or repeated measures ANOVA were significant at P < .05, except mean postovulation serum concentrations of LH, which were tested using the LSD test among groups on each day. Tukey's multiple comparison test was used to compare posttreatment AUC.
T-tests were used to compare LH peak heights and AUC between mares that ovulated and treated mares that did not ovulate and to compare posttreatment AUC between replicates within each treatment group. All analyses were performed using SAS (1988), except analyses of AUC and LH peak values after implant insertion (Minitab, 1991) .
Results
No replicate effect was detected for frequency of ovulation, development of a follicle 30 mm in diameter, or posttreatment AUC for LH; therefore, replicates were combined in all analyses. Fifteen of 100 mares ovulated during the 30-d posttreatment period. The number of mares that ovulated was greater ( P < .05) for the 3.6-( 7 ) or 5.4-( 6 ) mg implant groups than for the .9-( 0 ) or 0-( 0 ) mg implant groups (Table 1) . Two mares in the 1.8-mg group ovulated. One ovulating mare from the 3.6-mg group died 1 d after ovulation due to a rectal tear. All ovulating mares had increased serum concentrations of progesterone.
Mean size of the largest pretreatment follicle affected ovulation rate. Mares having follicles 5 15 mm in diameter were less likely ( P < .05) to ovulate (10 of 88, 11.3%) than those with follicles 16 to 20 mm in diameter ( 5 of 12, 41.6%, Table 2 ). For mares that ovulated, the interval from treatment to ovulation was shorter ( P < .05) for mares in the 5.4-mg (13 d ) than for those in the 1.8-mg group (22 d, Table 1 ).
There was no significant difference among groups in number of follicles of a given diameter (20 to 29, 30 to 39, or 40 to 49 mm) on a given palpation day. However, the size of the largest follicle that developed during the posttreatment observation period tended to vary among groups ( P = .068); the mean diameter of the largest follicle increased with increasing dose of GnRH (Table 3) . Overall, there was no significant effect of dose on the number of mares that developed a follicle 2 30 mm in diameter. However, when individual groups were compared by chi-square analyses using 2 x 2 tables, the 0-mg group had significantly fewer follicles 2 30 mm in diameter ( n = 1) than did mares in the 3.6-mg group ( n = 7 ) .
Serum concentrations of LH peaked in all groups of GnRH-treated mares on approximately d 12 after treatment (Figures 1 and 2) . Mean peak LH concentrations differed between control and treated mares ( P < .05), but were similar among all mares treated with GnRH analogue ( P > .05). Mean peak serum concentrations of LH were similar ( P = .39) between ovulating and nonovulating mares.
Average condition scores (approximately 5 on a scale of 1 to 9 ) were similar among groups at the beginning and end of treatment. Weight gains occurred in all groups and means ranged from 36 to 65 Dose of GnRH affected the area under the LH curve (Table 4) . Mean AUC for LH was greater ( P < .05) for all GnRH treatments than for the 0-mg group. In addition, mean AUC for LH in mares given 5.4 mg was greater ( P < .05) than that for all other groups kg. Figure 1 . Mean concentration of luteinizing hormone (LH) (nanograms/milliliter) in non-ovulating mares. Day 0 = day of treatment. Overall SEM = 8.7. Number of mares in each group were 20, 20, 18, 13, and 14 for 0, .9, 1.8, 3.6, and 5.4 mg of GnRH analogue/implant, respectively.
except the 3.6-mg group. Mean AUC did not differ between ovulating and nonovulating mares.
The interovulatory interval was shorter ( P < .05) for positive control mares than for treated mares that ovulated (Table 51, but no difference was found among the GnRH dose groups. Serum concentrations of progesterone on d 5, 8, and 11 after ovulation differed significantly over time and by group, but no time x group interaction was detected. The 5.4-mg group had the highest mean serum concentrations of progesterone on all days. Neither AUC for LH nor peak concentration of LH after GnRH challenge differed among groups.
Incidence of reaction to the implant did not seem to be dose-related. Three mares had palpable neck swellings, one each from the control, .9-, and 5.4-mg groups.
Discussion
Although preliminary studies using goserelin acetate t o induce ovulation in anestrous mares seemed promising, our results did not confirm reported ovulation rates. Mares in the present study had a dose-dependent increase in frequency of ovulation when treated with goserelin acetate. However, the increase was less consistent than previously reported by researchers using identical implants (Allen et al., 1987; Meyer et al., 1990; Turner and Irvine, 1991) . The number of mares ovulating increased when they were given 3.6-mg implants vs .9-mg implants. However, no improvement in ovulation rate was noted for mares given 5.4-vs 3.6-mg implants. In addition, the highest ovulation rate obtained (35%) was too low to be of managerial value. Allen et al. (1987) reported ovulation rates of 40 and 87% for mares given the .9-and 1.8-mg implants, respectively. Meyer et al. (1990) reported ovulation rates of 13, 41, 41, and 59% for 0, .9, 1.8, and 2.7 mg, respectively. Turner and Irvine (1991) reported ovulation rates of 5, 55, and 85% for mares administered 0, 3.6, and 5.4 mg, respectively. Both Meyer et al. (1990) and Turner and Irvine (1991) reported ovulations in mares given no goserelin, but only mares receiving GnRH analogue in the current study ovulated. This indicates that the discrepancy in ovulation rates among studies may be due to differences in depth of anestrus or early transition among mares at the time of treatment. Silvia et al. (1986) reported that size of the largest follicle was the best predictor of number of days to initial ovulation of the breeding season. Our study as well as previous studies (Ginther and Bergfelt, 1990; Ainsworth and Hyland, 199 1) demonstrated that mean size of the largest follicle before treatment affected ovulation rate regardless of treatment dose. Improvement in ovulation rate in response to GnRH or GnRH analogues could be accomplished by treating only the mares with follicles > 20 mm in diameter. Suppression of ovulation using goserelin at high doses ( 2 1.8 mg) was proposed by Allen et al. (1987) . However, Turner and Irvine (1991) using the same type of implants reported no suppressive effects with doses of 3.6 and 5.4 mg. Our results were consistent with the latter study, indicating no suppressive effect with the higher dose implants. In fact, we found a dose-dependent decrease in interval to ovulation consistent with previous studies (Meyer et al., 1990; Turner and Irvine, 1991) .
The cumulative secretion of LH over the 30-d posttreatment period (AUC increased with increasing dose of goserelin. However, even though the pituitary was responsive to GnRH, the implants did not increase releasable pituitary LH 33 or 34 d later. Therefore, our hypothesis that higher doses of GnRH analogue would increase releasable pituitary LH was not supported. Perhaps this was due to the constant release of goserelin instead of a more physiological pulsatile pattern (Turner and Irvine, 1991) . Alternatively, a treatment period of 28 d may not have been sufficient stimulation to increase releasable pituitary LH because mares were anestrous at the onset of treatment.
Concentrations of LH increased in response to goserelin to a peak at 12 d in ovulating and nonovulating mares. Others (Allen et al., 1987; Turner and Irvine, 1991) have reported shorter intervals to peak concentrations of LH in response to goserelin. This probably reflects the stage of transition to the breeding season and low pituitary stores of LH at the time of initiation of treatment for mares in the current study (Hart et al., 1984) .
Hyland et al. ( 19 8 7 ) found serum LH to be lower in nonovulating than in ovulating mares. However, similar concentrations of LH in ovulating and nonovulating mares given various doses of goserelin acetate have been reported (Meyer et al., 1990) and were consistent with our data, which showed no relationship between either peak concentration of LH or AUC and ovulation. For example, peak concentrations in the two 1.8-mg implant mares that ovulated (75.8 and 52.7 ng/mL of LH) were lower than mean peak concentrations in nonovulating mares treated with 1.8, 3.6, or 5.4 mg of goserelin. Perhaps the LH concentrations in individual mares failing to ovulate may not have fit the characteristic preovulatory pattern of a slow, sustained rise (Ginther, 1992) . More likely, failure to ovulate was due to inadequate follicular development at the time of greatest LH secretion.
There was no increase in follicular development for GnRH-treated mares on any day during the 28-d treatment period. The size of the largest follicle during the treatment period was similar among groups. Harrison et al. (1990) reported the number of follicles > 10 and > 20 mm in diameter from approximately d 10 to 25 after treatment to be less in mares implanted with GnRH analogue than in either control mares or those injected twice daily with GnRH analogue. In contrast, follicular development was increased in mares given frequent GnRH injections (Ginther and Bergfelt, 1990; Turner and Irvine, 1991) or pulsatile GnRH (Johnson, 1986) .
Based on concentrations of progesterone 5, 8, and 11 d after ovulation, the corpus luteum that formed in aMares exposed to a 16-h photoperiod. bic*dNumbers within a column lacking a common superscript differ ( P < .05).
response to goserelin apparently had normal steroidogenic capabilities. Others have reported normal pregnancies after GnRH-induced ovulations (Allen et al., 1987; Hyland et al., 1988; Ginther and Bergfelt, 1990; Meyer et al., 1990) . The reason(s) for the longer interval from the first t o second ovulation in treated mares was not determined. Perhaps receptors on the pituitary and(or) ovaries were down-regulated by continued exposure to GnRH analogue. More likely, however, mares returned to an anestrous state after exposure to exogenous GnRH ceased at 28 d due to the lack of seasonal maturity of the hypothalamic-pituitary-ovarian axis. McCue et al. (1991) found that ovulating and nonovulating mares treated with GnRH in January and February returned to anestrus. Although not critically examined, the nonovulating GnRHtreated mares in our study entered a prolonged anestrous period, as evidenced by decreased ovarian activity after the 28-d trial period.
In summary, goserelin implants increased the frequency of ovulation and serum concentrations of LH in a dose-dependent manner. However, incidence of ovulation was not high enough to be of managerial value. Perhaps ovulation rates could be improved by treating mares with GnRH later in transition when recrudescence of the hypothalamic-pituitary-ovarian axis has begun to occur and both exogenous and endogenous GnRH would participate in restoring pituitary LH. If mares are treated early in transition, then longer treatment periods or more physiological regimens (e.g., pulsatile GnRH patterns; Palmer and Quellier, 1988; Ginther, 1992) may be required for induction of ovulation.
Implications
This study indicates that the timing of treatment with 28-d implants of goserelin acetate will need to be modified to stimulate cyclicity in a predictable manner in a large proportion of anestrous mares. These data also indicate that goserelin acetate used to stimulate ovulations early in the breeding season may delay subsequent ovulations. Further studies are needed to assess the factors that affect the ovulatory response of mares to gonadotropin-releasing hormone analogue.
